/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION
MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES
LAWS./
VICTORIA, July 18, 2017 /CNW/ - Emerald Health
Therapeutics, Inc. (TSXV: EMH, OTCQX: EMHTF) ("Emerald" or the
"Company") announces that it has filed an amended and restated
final base shelf prospectus (the "Amended Prospectus") with
the securities regulatory authorities in the provinces of
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New
Brunswick, Nova Scotia,
Prince Edward Island and
Newfoundland and Labrador, amending and restating the base
shelf prospectus filed by the Company on January 25, 2017 (the "Original Prospectus") with
such securities regulatory authorities.
As announced on February 10, 2017,
April 20, 2017 and April 21, 2017, the Company has issued an
aggregate of $40,940,673 of
Securities (as defined below) under the Original Prospectus and
therefore, prior to the filing of the Amended Prospectus, had an
aggregate of $9,059,327 of Securities
unallocated under the Original Prospectus. The Amended Prospectus
will allow the Company, in the aggregate, to offer, from time to
time, up to $150,000,000 of
Securities of which $109,059,327 is
unallocated as of the date hereof during the period ending
February 25, 2019 that the Amended
Prospectus remains effective (the "Effective Period").
The Amended Prospectus will enable the Company to make offerings
of up to $150,000,000 of common
shares, preferred shares, debt securities, warrants, units or
subscription receipts of the Company (collectively, the
"Securities") or a combination thereof from time to time,
separately or together, in amounts, at prices and on terms to be
determined based on market conditions at the time of the offering
and as set out in an accompanying prospectus supplement during the
Effective Period. The specific terms of any future offering will be
established in a prospectus supplement to the Amended Prospectus,
which supplement will be filed with the applicable Canadian
securities regulatory authorities. The net proceeds from any sale
of any securities will be used for purposes as set out in the
applicable Amended Prospectus supplement.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualifications under the securities laws of any such
jurisdiction.
A copy of the Amended Prospectus can be found under the
Company's profile on sedar.com or may be obtained from the Company
upon written request from the contact below.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF)
operates primarily through Emerald Health Botanicals Inc.
("Botanicals"), a wholly owned subsidiary of the Company and a
Licensed Producer under the Access to Cannabis for Medical Purposes
Regulations (ACMPR). Botanicals is authorized to produce and sell
both dried medical cannabis flowers and medical cannabis oils in
Canada. Botanicals currently
operates an indoor facility in Victoria,
British Columbia, with plans for expansion on a 32-acre
property in Metro Vancouver and a joint venture with Village Farms
utilizing 25 acres of greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed
producers, with a team of highly qualified management experienced
in pharmaceutical drug discovery, development and distribution.
Emerald's vision is to be a leading provider of cannabis products
through its production capabilities, proprietary genetics and
intellectual property, value added products and branding, and
superb customer experience.
Please visit https://www.emeraldhealth.ca/ for more
information.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements. Forward-looking statements include, but are not
limited to, statements regarding the filing and effectiveness of
any potential prospectus supplement; the amount and terms of any
securities to be offered; the Company's plans for expansion; and
the Company's vision to be a leading provider of cannabis.
The Company does not intend, and does not assume any obligation,
to update these forward-looking statements except as required by
law. These forward-looking statements involve risks and
uncertainties relating to, among other things, the potential
offering of any securities by the Company; uncertainty with
respect to the completion of any future offering; the ability to
obtain applicable regulatory approval for any contemplated
offerings; the ability of the Company to negotiate and
complete future funding transactions; variations in market
conditions; failure of the federal government to approve
legislation legalizing sales of non-therapeutic adult-use cannabis;
failure to obtain Health Canada and other regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; the Company's historical experience with medical
marijuana operations; results of scientific research; uninsured
risks; regulatory changes; difficulties in construction or in
obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Amended Prospectus and the Company's
annual information form and other filing with the applicable
Canadian securities regulators, which may be viewed at
www.sedar.com. Actual results may differ materially from those
expressed or implied by such forward-looking statements.
"Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
SOURCE Emerald Health Therapeutics, Inc.